IP Verse

Cellectis patent opposition analysis

Latest patents of Cellectis opposed by its competitors

The following table provides an overview of the latest patents of Cellectis that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2997141Oct 12, 2022Cd19 Specific Chimeric Antigen Receptor And Uses Thereof1
EP3116902Jan 1, 2020Method For Generating T-Cells Compatible For Allogenic Transplantation4
EP3189073Dec 25, 2019Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy1
EP3126390Oct 16, 2019Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy1
EP3008186Nov 28, 2018Methods For Non-Transgenic Genome Editing In Plants4
EP3105317Sep 19, 2018Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells2
EP3004349Mar 28, 2018A Method For Producing Precise Dna Cleavage Using Cas9 Nickase Activity1
EP3004337Aug 2, 2017Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease System1

Top competitors of Cellectis